JP2016512960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512960A5 JP2016512960A5 JP2015560341A JP2015560341A JP2016512960A5 JP 2016512960 A5 JP2016512960 A5 JP 2016512960A5 JP 2015560341 A JP2015560341 A JP 2015560341A JP 2015560341 A JP2015560341 A JP 2015560341A JP 2016512960 A5 JP2016512960 A5 JP 2016512960A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cells
- talen
- gene
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 108020004414 DNA Proteins 0.000 claims 8
- 108010042407 Endonucleases Proteins 0.000 claims 8
- 102000004533 Endonucleases Human genes 0.000 claims 8
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims 8
- 206010064571 Gene mutation Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 238000010459 TALEN Methods 0.000 claims 6
- 239000000178 monomer Substances 0.000 claims 6
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 4
- 208000016361 genetic disease Diseases 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 101150056204 COL7A1 gene Proteins 0.000 claims 3
- 101100496573 Homo sapiens COL7A1 gene Proteins 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 claims 2
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 claims 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 230000003007 single stranded DNA break Effects 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 1
- 230000007035 DNA breakage Effects 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 108010026638 endodeoxyribonuclease FokI Proteins 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 210000002510 keratinocyte Anatomy 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019021260A JP6893945B2 (ja) | 2013-03-01 | 2019-02-08 | Ｔａｌｅｎに基づく遺伝子修正 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771735P | 2013-03-01 | 2013-03-01 | |
| US61/771,735 | 2013-03-01 | ||
| PCT/US2014/019322 WO2014134412A1 (en) | 2013-03-01 | 2014-02-28 | Talen-based gene correction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019021260A Division JP6893945B2 (ja) | 2013-03-01 | 2019-02-08 | Ｔａｌｅｎに基づく遺伝子修正 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512960A JP2016512960A (ja) | 2016-05-12 |
| JP2016512960A5 true JP2016512960A5 (enExample) | 2017-03-30 |
| JP6480874B2 JP6480874B2 (ja) | 2019-03-13 |
Family
ID=51428832
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560341A Expired - Fee Related JP6480874B2 (ja) | 2013-03-01 | 2014-02-28 | Ｔａｌｅｎに基づく遺伝子修正 |
| JP2019021260A Expired - Fee Related JP6893945B2 (ja) | 2013-03-01 | 2019-02-08 | Ｔａｌｅｎに基づく遺伝子修正 |
| JP2021015441A Pending JP2021088565A (ja) | 2013-03-01 | 2021-02-03 | Ｔａｌｅｎに基づく遺伝子修正 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019021260A Expired - Fee Related JP6893945B2 (ja) | 2013-03-01 | 2019-02-08 | Ｔａｌｅｎに基づく遺伝子修正 |
| JP2021015441A Pending JP2021088565A (ja) | 2013-03-01 | 2021-02-03 | Ｔａｌｅｎに基づく遺伝子修正 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9393257B2 (enExample) |
| EP (2) | EP3567104A1 (enExample) |
| JP (3) | JP6480874B2 (enExample) |
| AU (2) | AU2014223243B2 (enExample) |
| CA (1) | CA2902954A1 (enExample) |
| ES (1) | ES2750550T3 (enExample) |
| WO (1) | WO2014134412A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9850497B2 (en) * | 2013-11-04 | 2017-12-26 | Regents Of The University Of Minnesota | Gene targeting methods and tools |
| JP2017510542A (ja) | 2014-01-31 | 2017-04-13 | ファクター バイオサイエンス インコーポレイテッド | 核酸生成及び送達のための方法及び製品 |
| IL297773B2 (en) | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| EP3543339A1 (en) | 2015-02-13 | 2019-09-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN104726495B (zh) * | 2015-03-25 | 2018-06-19 | 西北农林科技大学 | 一种基于talen介导的基因打靶敲除山羊blg的载体及重组细胞 |
| US20180080051A1 (en) | 2015-03-31 | 2018-03-22 | Exeligen Scientific, Inc. | Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism |
| US11845928B2 (en) | 2015-05-04 | 2023-12-19 | Tsinghua University | Methods and kits for fragmenting DNA |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| WO2017075248A1 (en) * | 2015-10-27 | 2017-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of epidermolysis bullosa by injection of autologous collagen vii overexpressing leukocytes |
| PT3377637T (pt) * | 2016-04-08 | 2020-06-17 | Krystal Biotech Inc | Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele |
| AU2017261804A1 (en) | 2016-05-12 | 2018-11-29 | Adicet Therapeutics, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3033788A1 (en) | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2017382902A1 (en) | 2016-12-21 | 2019-07-18 | TCR2 Therapeutics Inc. | Engineered T cells for the treatment of cancer |
| US12344826B2 (en) | 2017-01-25 | 2025-07-01 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Apparatus and methods for in vitro preclinical human trials |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| EP3585897A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders |
| FI3638776T3 (fi) | 2017-06-14 | 2025-12-09 | Univ Dresden Tech | Menetelmiä ja välineitä genomien geneettiseen muokkaamiseen hyödyntäen suunnittelu-DNA:ta rekombinoivia entsyymejä |
| JP7712643B2 (ja) | 2017-06-19 | 2025-07-24 | 国立大学法人東北大学 | 表皮水疱症の治療剤 |
| EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| AU2018370120C1 (en) | 2017-11-15 | 2024-05-30 | Adicet Therapeutics, Inc. | Methods for selective expansion of d3 yd T-cell populations and compositions thereof |
| WO2019200163A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| EP3781677A4 (en) | 2018-04-16 | 2022-01-19 | University of Massachusetts | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING |
| AU2019260757B2 (en) | 2018-04-27 | 2023-09-28 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| EP4252759B1 (en) | 2018-05-11 | 2025-08-06 | Memorial Sloan Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| WO2019234750A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of regenerating and transforming cannabis |
| EP3802839A1 (en) | 2018-06-07 | 2021-04-14 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Nucleic acid constructs and methods of using same |
| WO2020051453A1 (en) * | 2018-09-07 | 2020-03-12 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| AU2019346549B2 (en) | 2018-09-24 | 2024-09-12 | Krystal Biotech, Inc. | Compositions and methods for the treatment of Netherton Syndrome |
| EP3887395A4 (en) | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
| EP3890757A1 (en) | 2018-12-03 | 2021-10-13 | Adicet Bio Inc. | Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof |
| BR112021014400A2 (pt) | 2019-02-08 | 2021-09-21 | Krystal Biotech, Inc. | Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, e, métodos para intensificar, aumentar, elevar e/ou suplementar os níveis de um polipeptídeo cftr em uma ou mais células, para reduzir ou inibir a destruição progressiva do pulmão, para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de fibrose cística e para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de copd |
| SG11202110956RA (en) | 2019-04-05 | 2021-10-28 | Rootpath Genomics Inc | Compositions and methods for t-cell receptor gene assembly |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| EP3987024A4 (en) | 2019-06-20 | 2023-11-01 | University Of Massachusetts | COMPOSITIONS AND METHODS FOR ENHANCED GENOMIC EDITING |
| CN114245745A (zh) | 2019-06-20 | 2022-03-25 | 纪念斯隆-凯特琳癌症中心 | 靶向pik3ca突变的t细胞受体及其用途 |
| US12344572B2 (en) | 2019-07-03 | 2025-07-01 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| US20220267737A1 (en) | 2019-07-18 | 2022-08-25 | University Of Rochester | Cell-type selective immunoprotection of cells |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| CN114981409A (zh) | 2019-09-03 | 2022-08-30 | 美洛德生物医药公司 | 用于基因组整合的方法和组合物 |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| JP2023531537A (ja) | 2020-06-30 | 2023-07-24 | メンドゥス・ベスローテン・フェンノートシャップ | 卵巣癌ワクチンでの白血病由来細胞の使用 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| CA3191396A1 (en) | 2020-09-01 | 2022-03-10 | Alexis ROVNER | Mammalian cells and methods for engineering the same |
| WO2022087380A1 (en) | 2020-10-23 | 2022-04-28 | Rootpath Genomics, Inc. | Compositions and methods for t-cell receptor identification |
| CN116981697A (zh) | 2021-01-14 | 2023-10-31 | 森迪生物科学公司 | 可分泌有效载荷调节 |
| EP4281102A1 (en) | 2021-01-22 | 2023-11-29 | Mendus B.V. | Methods of tumor vaccination |
| CA3212351A1 (en) | 2021-03-12 | 2022-09-15 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
| CA3213789A1 (en) | 2021-04-02 | 2022-10-06 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
| CA3218780A1 (en) | 2021-05-11 | 2022-11-17 | Daniel Getts | Methods and compositions for genomic integration |
| EP4430206A1 (en) | 2021-11-10 | 2024-09-18 | Encodia, Inc. | Methods for barcoding macromolecules in individual cells |
| US20250205335A1 (en) | 2022-03-17 | 2025-06-26 | Hangzhou Chengyuan Biotechnology Co., Ltd. | Synthetic tumor-infiltrating lymphocytes (tils) |
| EP4573114A2 (en) | 2022-08-19 | 2025-06-25 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| KR20250126156A (ko) | 2022-11-18 | 2025-08-22 | 교토후고리츠다이가쿠호진 | 미토파지 유도를 위한 조성물 및 그의 용도 |
| WO2025128981A1 (en) | 2023-12-14 | 2025-06-19 | Sohm, Inc. | Compositions and methods for genome editing |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040161817A1 (en) * | 2001-06-04 | 2004-08-19 | Corixa Corporation | Compositions and methods for high-level, large-scale production of recombinant proteins |
| EP3456826B1 (en) * | 2009-12-10 | 2023-06-28 | Regents of the University of Minnesota | Tal effector-mediated dna modification |
| AU2010360293B2 (en) | 2010-09-06 | 2016-06-16 | Temasek Life Sciences Laboratory Limited | Molecular interaction between Xa10 and AvrXa10 |
| AU2011325956B2 (en) * | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| CA2848417C (en) | 2011-09-21 | 2023-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
-
2014
- 2014-02-28 ES ES14756449T patent/ES2750550T3/es active Active
- 2014-02-28 AU AU2014223243A patent/AU2014223243B2/en not_active Ceased
- 2014-02-28 CA CA2902954A patent/CA2902954A1/en not_active Abandoned
- 2014-02-28 US US14/193,037 patent/US9393257B2/en not_active Expired - Fee Related
- 2014-02-28 EP EP19180371.7A patent/EP3567104A1/en not_active Withdrawn
- 2014-02-28 JP JP2015560341A patent/JP6480874B2/ja not_active Expired - Fee Related
- 2014-02-28 WO PCT/US2014/019322 patent/WO2014134412A1/en not_active Ceased
- 2014-02-28 EP EP14756449.6A patent/EP2961262B1/en active Active
-
2016
- 2016-06-15 US US15/182,773 patent/US10172880B2/en not_active Expired - Fee Related
-
2018
- 2018-10-31 US US16/176,073 patent/US10973844B2/en not_active Expired - Fee Related
-
2019
- 2019-02-08 JP JP2019021260A patent/JP6893945B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-16 AU AU2020200307A patent/AU2020200307A1/en not_active Abandoned
-
2021
- 2021-02-03 JP JP2021015441A patent/JP2021088565A/ja active Pending
- 2021-03-04 US US17/191,864 patent/US20210187006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512960A5 (enExample) | ||
| McCutcheon et al. | Epigenome editing technologies for discovery and medicine | |
| CN107208078B (zh) | 使用成对向导rna进行靶向遗传修饰的方法和组合物 | |
| US10294494B2 (en) | Methods and compositions for modifying a targeted locus | |
| Gratz et al. | CRISPR‐Cas9 genome editing in Drosophila | |
| Doyle et al. | TAL effectors: highly adaptable phytobacterial virulence factors and readily engineered DNA-targeting proteins | |
| Puchta | Using CRISPR/Cas in three dimensions: towards synthetic plant genomes, transcriptomes and epigenomes | |
| JP2017070287A5 (enExample) | ||
| JP2016500262A5 (enExample) | ||
| US20170073663A1 (en) | Targeted remodeling of prokaryotic genomes using crispr-nickases | |
| EP3222728A1 (en) | Method for regulating gene expression using cas9 protein expressed from two vectors | |
| JP2016027807A5 (enExample) | ||
| EP4407034A3 (en) | Compositions and methods for modifying genomes | |
| JP2018530336A5 (enExample) | ||
| JP2016521993A5 (enExample) | ||
| FI3690056T3 (fi) | Menetelmiä ja tuotteita nukleiinihapon valmistamiseksi ja viemiseksi | |
| MY210289A (en) | Compositions and methods for modifying genomes | |
| JP2013513389A5 (enExample) | ||
| JP2020519304A5 (enExample) | ||
| Hu et al. | Targeting human microRNA genes using engineered Tal-effector nucleases (TALENs) | |
| HRP20240657T1 (hr) | Materijali i postupci za liječenje hemoglobinopatija | |
| Andrey et al. | CRISPR/Cas9 genome editing in embryonic stem cells | |
| Kuwayama | Enhancement of homologous recombination efficiency by homologous oligonucleotides | |
| Gibson et al. | What rheumatologists need to know about CRISPR/Cas9 | |
| JP2020511931A5 (enExample) |